Asimov Introduces its AI-driven 4th Generation CHO Edge System with Increased Titer Guarantee
July 30 2024 - 9:28AM
Business Wire
- Enables unique vector and process optimizations for different
molecules to increase the likelihood of high titer clonal cell
lines.
- Asimov now guarantees titers of 5 g/L for IgG monoclonal
antibodies, as part of its Cell Line Development (CLD) Service
Asimov, the synthetic biology company advancing the design and
manufacture of therapeutics, today announced the launch of its
fourth generation CHO Edge System. With an increased typical titer
range of 5-11 g/L across modalities before any upstream process
optimization, the new system has been developed to optimize
expression across a breadth of biologic architectures and increase
the likelihood of high titer cell lines.
The system’s improved robustness has allowed Asimov to increase
its minimum CLD titer guarantee for IgG monoclonal antibodies to 5
g/L. If the lead clone does not hit this benchmark, it is still
transferred to the partner, but the service fee and all commercial
use license fees are waived.
The 4th generation CHO Edge System updates expression vector
architectures, genetic parts selection, and process methodologies.
In addition, the new system incorporates a suite of AI models to
predict signal peptide cleavage, RNA splicing, and upstream process
optimization. Customers can access these advanced capabilities by
licensing the CHO Edge System or as part of Asimov’s Cell Line
Development Service.
Alec Nielsen, co-founder and CEO of Asimov said, “Our 4th
generation CHO Edge System incorporates learnings from a wide range
of molecules, and an array of proprietary data-driven AI models. We
have upgraded the vector architectures, genetic parts selection,
and predictive modeling across multiple biological processes. While
we always target titers in excess of 10 g/L in our CLD process, we
can now guarantee a minimum of 5 g/L for IgG molecules. By offering
a titer guarantee, we aim to set a new standard for cell line
development in the industry and redefine the expectations of
therapeutic developers.”
The CHO Edge System incorporates a GMP-banked CHO-K1 GS
knock-out host (or a GS-Fut8 double knockout), a hyperactive
transposase, a library of >1000 characterized genetic parts and
advanced computational models. Asimov reliably generates stable
cell lines with high titer and product quality by using the CHO
Edge System to optimize the expression vector across
modalities.
For more information about Asimov and the CHO Edge System,
please visit https://www.asimov.com/cho.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240730374149/en/
Chris Thorne Asimov Email: chris.thorne@asimov.com
Francesca Wallace Email:
francesca.wallace@zymecommunications.com